3.1. Analysis.
Comparison 3 ICS versus placebo, parallel‐group studies, 2 months or less (all doses), Outcome 1 Change in FEV1 compared to baseline (% increase).
Comparison 3 ICS versus placebo, parallel‐group studies, 2 months or less (all doses), Outcome 1 Change in FEV1 compared to baseline (% increase).